If a drug is rapidly absorbed due to high lipid solubility and enters the lymphatics, what is the likely impact on bioavailability after oral administration?

• A. Decreased bioavailability due to rapid distribution
• B. Bypassing first-pass metabolism can increase bioavailability
• C. No absorption occurs
• D. It requires higher dose than non-lymphatic absorption

Answer: (B)

When a drug is absorbed via the intestinal lymphatics, it enters the systemic circulation through the thoracic duct, effectively bypassing the hepatic portal system. This means it avoids much of the liver’s first-pass metabolism, so more of the dose reaches the bloodstream intact. Lipid-soluble drugs load into chylomicrons in enterocytes, which explains their lymphatic uptake. As a result, oral bioavailability can increase because presystemic (liver) metabolism is reduced. The other ideas—that rapid distribution lowers bioavailability, that no absorption occurs, or that a higher dose is required due to lymphatic uptake—don’t align with this bypass of first-pass metabolism that raises the amount reaching systemic circulation.